Skip to main content
CMG Pharmaceutical Co., Ltd. logo

CMG Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 058820 ISIN · KR7058820002 KO Manufacturing
Open in API
Filings indexed 165 across all filing types
Latest filing 2024-03-13 AGM Information
Country KR South Korea
Listing KO 058820

About CMG Pharmaceutical Co., Ltd.

http://www.cmgpharma.co.kr

CMG Pharmaceutical Co., Ltd. is a pharmaceutical company specializing in the development of advanced drug delivery systems. The company's core competency is its Oral Thin Film (OTF), or Orally Dissolving Film (ODF), technology platform. This technology is used to develop improved new drugs, new formulations, and combination therapies designed to enhance patient convenience and efficacy. The company's portfolio includes prescription medications and general pharmaceuticals. As an affiliate of CHA Health Systems, CMG Pharmaceutical is actively engaged in research and development, managing a pipeline of drug candidates and conducting clinical trials.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal notification filed by CMG Pharmaceutical regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the reasons for choosing this date despite regulatory requests for dispersion. As this is a regulatory disclosure regarding meeting logistics and compliance rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2024-03-13 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for CMG Pharmaceutical. It contains the agenda for the 23rd Annual General Meeting, including items such as the approval of financial statements, election of directors, and remuneration limits. It also includes detailed management information, business outlook, and financial statements (balance sheet, income statement, statement of changes in equity) as required for shareholder review prior to the meeting. This type of document is classified as a Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information to vote on meeting agenda items.
2024-03-13 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit proxies from shareholders for an upcoming Annual General Meeting (AGM). It contains details about the meeting date, agenda items (such as approval of financial statements, election of directors, etc.), and instructions for voting. While it contains financial data, this is provided as part of the proxy solicitation materials for the AGM, not as a standalone annual report. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2024-03-13 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from CMG Pharmaceutical regarding a significant change in financial structure (revenue/profit/loss). It provides a summary table of financial results comparing the current fiscal year to the previous one, including revenue, operating profit, and net income. This type of disclosure is a standard regulatory requirement in South Korea for listed companies to announce preliminary financial results before the final audit is completed. It fits the definition of an Earnings Release (ER) as it provides key financial highlights for the period. FY 2023
2024-02-14 Korean
[기재정정]유형자산취득결정(자율공시)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from CMG Pharmaceutical regarding the acquisition of tangible assets (land and building). It details the transaction, the purpose of the acquisition, the payment schedule, and a correction notice regarding the acquisition date. Since this is a specific corporate disclosure regarding asset acquisition and does not fit into categories like M&A (which usually refers to corporate mergers/takeovers) or other specific financial reports, it falls under the general regulatory filing category.
2024-01-11 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for an upcoming Annual General Meeting (AGM). It does not contain the full AGM materials or proxy statements, but rather serves as a formal regulatory notice of the procedural steps for the meeting. Given the nature of the announcement as a regulatory disclosure, it fits best under the RNS category.
2023-12-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.